Clinical trial NCT06650436: DEliriuM in STroke: the Link Between Stroke, Delirium and Long-term Cognitive Impairment
Official title: DEliriuM in STroke: the Link Between Stroke, Delirium and Long-term Cognitive Impairment
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Ischemic Stroke
Delirium
Cognitive Impairment
Keywords: Post stroke delirium
Post-stroke cognitive impairment
EEG
Delirium
Ischemic Stroke
Cognitive Impairment
Lead sponsor: Universitair Ziekenhuis Brussel
Sponsor class: OTHER
Collaborators: name: Vrije Universiteit Brussel
name: UMC Utrecht
First posted: 2024-10-21
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients hospitalized at the stroke unit of UZ Brussel, who can be included within 72 hours after stroke symptom onset.

Brief summary: Primary objective of this study:

determine whether PSD is a risk factor for PSCI, independent of brain frailty and premorbid cognitive functioning.

Secondary objectives:

1. to investigate the role of infarct location, imaging markers of brain frailty and brain network disintegration in the development of PSD;
2. to investigate the role of persistent brain network disintegration in the development of PSCI.

Detailed description: 1. Patient characteristics such as age, (premorbid) modified Rankin Scale (mRS) and stroke characteristics such as stroke severity (NIHSS) will be documented. There will be screened for preexisting cognitive decline (by using a Dutch shortened and validated version of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). Clinical assessments such as NIHSS and mRS will be repeated after 3 and 12 months, as part of regular care. Comorbid conditions will be documented during the whole duration of the study.
2. Previous or concomitant use of drugs will be registered, in particular those known to affect cognitive function, such as anticholinergic drugs, analgo-sedatives or benzodiazepines.
3. Delirium assessment during hospitalization: delirium assessment will be performed twice a day, at the beginning and ending of each day shift with a minimal interval of 5 hours between the two evaluations each day, during the first 72 hours after ischemic stroke onset. The length of the screening period is based on the results of a prospective observational study that showed that almost all of PSD cases occurred within 72 hours (98%). If a patient develops delirium during the first 72 hours after stroke onset, delirium monitoring will be continued until 4 negative screening tests are obtained (because of possible fluctuations of delirium signs) or until the end of the hospitalization. Delirium assessments will be performed by a trained nurse using the 4 'A's Test (4AT) and the Richmond Agitation and Sedation Scale (RASS). The RASS will be used to determine the type of delirium, with negative RASS scores indicating hypoactive delirium and a positive RASS score indicating hyperactive delirium.
4. EEG recordings will be performed by a trained neurophysiology nurse, using 21 electrodes placed according to the 10-20 system, with 10 minutes eyes open and 10 minutes eyes closed, within one hour of the clinical evaluation during the hospitalization. The first EEG will be routinely recorded during the first 24 hours after stroke onset. A second EEG will be only be recorded in patients who develop PSD between 24 and 72 hours after stroke onset. EEG's recorded during hospitalization are considered standard of care. EEG recording will be repeated at 12 months.
5. MRI of the brain will be performed during hospitalization (=standard of care) and 12 months after stroke onset. Standard acute stroke imaging will involve a 3-T MR scanner with sagittal 3DFLAIR (fluid-attenuated inversion recovery) sequence, T2 sequence fossa posterior with a slice thickness of 2mm, axial diffusion sequence (slice thickness 4mm), 3D-SWI (susceptibility weighted imaging) sequence (slice thickness 2mm) and 3D-QALAS sequence. Manual segmentation of the acute ischemic lesion will be performed on MRI scans of the brain, performed during hospitalization for IS. Patients without visible acute ischemic lesions on MRI will be excluded. Acute ischemic stroke lesions (AIL) are defined by the presence of a hyperintense MRI diffusion-weighted imaging (DWI) lesion with corresponding hypointensity in apparent diffusion coefficient map (ADC). The DWI and ADC images may also help to discriminate between new ischemic lesions and pre-existent white matter hyperintensities. Prior to performing the segmentations for the current study, the reviewer will delineate AIL on 10 scans twice with an interval of 1 month, with the aim to optimize intraobserver agreement. Visual rating of white matter hyperintensities (Fazekas scale) and cerebral atrophy (global cortical atrophy (GCA) scale) as markers of brain frailty.
6. Cognitive and mood assessment: neuropsychological assessment will take place at 3 months and 12 months after the IS. A trained nurse will administer the Montreal Cognitive Assessment (MOCA, Dutch or French version) at these time intervals. She will be blinded for the initial occurrence of delirium. Depression screening will be performed at the same time intervals by using the Patient Health Questionnaire-2 and the Hospital Anxiety and Depression Scale (HADS) (in order to be able to compare with previously performed delirium studies).

Eligibility criteria: Inclusion Criteria:

* 18 years or older,
* clinical diagnosis of first-ever ischemic stroke (onset \<72h at time of inclusion),
* admitted at stroke unit of UZ Brussel,
* ability to participate in cognitive assessments,
* fluency in Dutch or French,
* ability to undergo an EEG during the first 24 hours after onset of stroke symptoms,
* ability to undergo MRI of the brain.

Exclusion Criteria:

* epilepsy history,
* pre-existing, space occupying brain lesion (except small meningeoma),
* pregnancy or wish to become pregnant,
* severe language impairment or dementia impeding cognitive assessment, life expectancy of less than 1 year.

Primary outcomes:
measure: Post-stroke delirium
timeFrame: first 72 hours after stroke symptom onset
measure: The role of brain network disintegration in post-stroke delirium: electrical analysis of the relative power in the alfa frequency band
timeFrame: first 72 hours after stroke symptom onset
measure: The role of brain network disintegration in post-stroke delirium: electrical analysis of the relative power in the beta frequency band
timeFrame: first 72 hours after stroke symptom onset
measure: The role of brain network disintegration in post-stroke delirium: electrical analysis of the relative power in the delta frequency band
timeFrame: first 72 hours after stroke symptom onset
measure: The role of brain network disintegration in post-stroke delirium: electrical analysis of the relative power in the theta frequency band
timeFrame: first 72 hours after stroke symptom onset
measure: The role of brain network disintegration in post-stroke delirium: electrical analysis of the relative power in the peak frequency band
timeFrame: first 72 hours after stroke symptom onset
measure: The role of brain network disintegration in post-stroke delirium: electrical analysis of the phase lag index (PLI)
timeFrame: first 72 hours after stroke symptom onset
measure: Post-stroke cognitive impairment
timeFrame: 3 months and 12 months after stroke symptom onset
measure: Post-stroke depression
timeFrame: 3 months and 12 months after stroke symptom onset
measure: Post-stroke depression
timeFrame: 3 months and 12 months after stroke symptom onset
measure: Markers of brain frailty
timeFrame: First 72 hours and 12 months after stroke symptom onset
Secondary outcomes:
measure: Key drivers of post-stroke delirium.
timeFrame: 12 months after stroke symptom onset
measure: Role infarct location
timeFrame: 12 months after stroke symptom onset
measure: Key drivers of post-stroke cognitive impairment.
timeFrame: 12 months after stroke symptom onset
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Universitair Ziekenhuis Brussel
Study officials:
References: